Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

NCT02587650 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Funding

Conditions

ALK Fusion Protein Expression
BRAF wt Allele
Invasive Skin Melanoma
MET Fusion Gene Positive
NRAS wt Allele
NTRK1 Fusion Positive
NTRK2 Fusion Positive
NTRK3 Fusion Positive
RET Fusion Positive
ROS1 Fusion Positive
Stage III Cutaneous Melanoma
Stage IIIA Cutaneous Melanoma
Stage IIIB Cutaneous Melanoma
Stage IIIC Cutaneous Melanoma
Stage IV Cutaneous Melanoma

Interventions

DRUG: Capmatinib
DRUG: Ceritinib
DRUG: Entrectinib
OTHER: Laboratory Biomarker Analysis
DRUG: Regorafenib

Sponsor

University of California, San Francisco